We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+34.4%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3.43B
AUM Growth
+$283M
(+9%)
Cap. Flow
-$809M
Cap. Flow
% of AUM
-23.57%
Top 10 Holdings %
Top 10 Hldgs %
38.81%
Holding
112
New
24
Increased
11
Reduced
35
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$67.2M |
| 2 |
Larimar Therapeutics
LRMR
|
+$59.9M |
| 3 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$29.8M |
| 4 |
GBIO
Generation Bio
GBIO
|
+$26.4M |
| 5 |
RNAM
Avidity Biosciences
RNAM
|
+$25.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AdaptHealth
AHCO
|
+$264M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$168M |
| 3 |
Q32 Bio
QTTB
|
+$62.7M |
| 4 |
ABMD
Abiomed Inc
ABMD
|
+$54.6M |
| 5 |
IMMU
Immunomedics Inc
IMMU
|
+$45.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.56% |
| 2 | Financials | 0.55% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Viatris
VTRS
$20.1B
| $195M | 5.69% |
12,151,362
| – | – |
|
2
Schrodinger
SDGR
$1.14B
| $123M | 3.59% |
1,346,167
| – | – |
|
|
DFPHU
3
DELISTED
DFP Healthcare Acquisitions Corp. Unit
DFPHU
| $112M | 3.25% |
10,460,000
| – | – |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $108M | 3.16% |
1,951,211
-3,937,300
| -67% | -$168M |
|
|
IMMU
5
DELISTED
Immunomedics Inc
IMMU
| $90.8M | 2.64% |
2,561,000
-1,546,464
| -38% | -$45.2M |
|
6
Pacira BioSciences
PCRX
$1.01B
| $87.3M | 2.54% |
1,663,000
+35,479
| +2% | +$1.48M |
|
|
HOLX
7
DELISTED
Hologic
HOLX
| $78.1M | 2.27% |
+1,370,186
| New | +$67.2M |
|
|
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $68M | 1.98% |
704,000
+357,591
| +103% | +$29.8M |
|
9
Mirum Pharmaceuticals
MIRM
$7.25B
| $67.1M | 1.95% |
3,448,912
| – | – |
|
|
10
Larimar Therapeutics
LRMR
$384M
| $66.1M | 1.93% |
+5,144,539
| New | +$59.9M |
|
11
Revolution Medicines
RVMD
$39.6B
| $56.7M | 1.65% |
1,796,383
| – | – |
|
12
Centene
CNC
$32.8B
| $56.3M | 1.64% |
886,000
-381,206
| -30% | -$24.8M |
|
13
Rhythm Pharmaceuticals
RYTM
$7.31B
| $55.1M | 1.6% |
2,470,013
-561,552
| -19% | -$10.9M |
|
|
SWTX
14
DELISTED
SpringWorks Therapeutics
SWTX
| $51.8M | 1.51% |
1,234,262
+446,019
| +57% | +$15.9M |
|
|
AXNX
15
DELISTED
Axonics, Inc. Common Stock
AXNX
| $49.5M | 1.44% |
1,408,603
-385,991
| -22% | -$13.3M |
|
|
ORTX
16
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $43.6M | 1.27% |
725,999
-160,226
| -18% | -$14.7M |
|
17
McKesson
MCK
$98.5B
| $42.7M | 1.24% |
278,085
+102,648
| +59% | +$14.8M |
|
18
Vericel Corp
VCEL
$2.38B
| $42.3M | 1.23% |
3,057,161
-1,389,948
| -31% | -$18.8M |
|
19
Brookdale Senior Living
BKD
$3.58B
| $41M | 1.2% |
13,910,899
-4,491,456
| -24% | -$14.5M |
|
20
Alector
ALEC
$167M
| $41M | 1.19% |
1,676,997
-62,000
| -4% | -$1.71M |
|
|
RETA
21
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $40.8M | 1.19% |
261,765
+77,900
| +42% | +$11.8M |
|
|
XLRN
22
DELISTED
Acceleron Pharma
XLRN
| $40.2M | 1.17% |
421,619
+78,619
| +23% | +$7.58M |
|
|
VIVO
23
DELISTED
Meridian Bioscience Inc
VIVO
| $38.7M | 1.13% |
+1,663,000
| New | +$24.1M |
|
|
XENT
24
DELISTED
Intersect ENT, Inc
XENT
| $34.9M | 1.02% |
2,576,879
-181,388
| -7% | -$2.11M |
|
25
Editas Medicine
EDIT
$457M
| $34.3M | 1% |
1,158,841
| – | – |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q2 2020 Portfolio in Review
As of Q2 2020, Deerfield Management held 112 positions worth $3.43B, up 9% from $3.15B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Deerfield Management withdrew a net $809M in Q2 2020, closing 19 positions and reducing 35 holdings. Its most notable exit was Q32 Bio, an estimated $62.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 72% a quarter earlier, followed by Financials and Technology.
Against the trend, Deerfield Management opened a new position in Hologic worth $78.1M.
- Deerfield Management's largest Q2 2020 buy was Hologic: 1,370,186 shares worth $78.1M.
- Deerfield Management added most to MyoKardia, Inc. Common Stock in Q2 2020, an estimated $29.8M increase.
- Deerfield Management's biggest Q2 2020 reduction was AdaptHealth, cutting an estimated $264M.
- Deerfield Management fully exited Q32 Bio in Q2 2020, selling an estimated $62.7M.
- Deerfield Management's ten largest holdings make up 39% of its $3.43B portfolio in Q2 2020.
- Deerfield Management opened 24 new positions and closed 19 in Q2 2020.
- Deerfield Management's portfolio value rose 9% quarter-over-quarter to $3.43B.
Based on Deerfield Management's 13F filing for Q2 2020, filed 14 Aug 2020.